Clinical Trial Update: Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

View source ↗

Summary

Expanded-access update for Leap Therapeutics' DKN-01 in advanced solid tumors, noting the program is no longer available and targeting multiple cancer types.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Carcinosarcoma
• Endometrial Cancer
• Esophageal Cancer
• Gastric Adenocarcinoma
• Gastric Cancer
• Ovarian Cancer
• Squamous Cell Carcinoma

Drugs mentioned

• DKN-01 (dkn-01)

Snippet

Sponsor: Leap Therapeutics, Inc. | Conditions: Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction | Status: NO_LONGER_AVAILABLE